title: [Effects of trimetazidine therapy on left ventricular function after percutaneous coronary intervention].
abstract: OBJECTIVE
  To explore the effects of trimetazidine therapy on left ventricular (LV) function after percutaneous coronary intervention (PCI).
  
  
  METHODS
  A total of 106 patients with unstable angina pectoris underwent successful elective PCI were randomly assigned to standard therapy group (control, n = 55) or trimetazidine group (n = 51, 60 mg trimetazidine loading dose prior to PCI followed by 20 mg Tid after PCI on top of standard therapy). cTnI level was measured before and at 16-18 hours after PCI. LV function was evaluated by echocardiography and major adverse cardiac events (MACE, including death, re-infarction and target vessel revascularization) at 12 months after PCI was compared between the two groups.
  
  
  RESULTS
  Post procedural cTnI level increased from [0.02 (0.01, 0.03)] µg/L at baseline to [0.11 (0.07, 0.13)] µg/L (P < 0.05) at 16-18 hours in the trimetazidine group, while [0.02(0.01, 0.03)] µg/L to [1.31(0.44, 2.31)] µg/L in the control group (P < 0.05). Post procedural cTnI level was significantly reduced in the trimetazidine group compared to the control group (P < 0.05). At 12 months follow-up, left ventricular ejection fraction in the trimetazidine group was significantly higher than in control group [(65.65 ± 3.94)% vs. (62.29 ± 3.06)%, P < 0.01] while incidence of MACE was similar between the two groups.
  
  
  CONCLUSIONS
  Trimetazidine can reduce the post-PCI cTnI release and improve left ventricular function after PCI in patients with unstable angina pectoris.
authors.affiliation: Department of Cardiology, Affiliated Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease, Beijing 100029, China.
authors.forename: Xiao-han
authors.initials: XH
authors.lastname: Xu
authors.forename: Wei-jun
authors.initials: WJ
authors.lastname: Zhang
authors.forename: Yu-jie
authors.initials: YJ
authors.lastname: Zhou
authors.forename: Zhi-ming
authors.initials: ZM
authors.lastname: Zhou
authors.forename: Han-ying
authors.initials: HY
authors.lastname: Ma
authors.forename: Bin
authors.initials: B
authors.lastname: Hu
authors.forename: Yun-peng
authors.initials: YP
authors.lastname: Kang
authors.forename: Fang-fang
authors.initials: FF
authors.lastname: Luo
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D062645:Percutaneous Coronary Intervention; D011184:Postoperative Period; D011446:Prospective Studies; D014292:Trimetazidine / Q000627:therapeutic use*; D016277:Ventricular Function, Left / Q000187:drug effects*
chemical_list: D014292:Trimetazidine